BIOLIFE SOLUTIONS INC (BLFS): Results of Operations and Financial Condition
BIOLIFE SOLUTIONS INC (BLFS) filed an SEC Form 8-K — Results of Operations and Financial Condition. BioLife Solutions Reports Second Quarter 2026 Financial Results Total revenue of $28.5 million, up 21% over Q2 2025 GAAP gross margin of 64% and non-GAAP adjusted gross margin of 65% GAAP net income of $45.1 million, inclusive of a $42.4 million non-cash income tax benefit, and n
How this was made
The 30-second read
Why it matters
Traders should treat this as a combined earnings and M&A catalyst. The definitive agreement and stated consideration create a new valuation framework tied to deal-close probability and timing, while the quarter’s operating improvements provide supporting context.
Market read
Definitive takeout terms plus Q2 profitability metrics can drive immediate repricing, with subsequent trading focused on approvals and deal-spread behavior into Q4 2026.
What to watch
Deal-close timing depends on stockholder and regulatory approvals; any delay or regulatory friction could widen the spread and pressure BLFS even if quarterly results look stronger.
Total revenue of $28.5 million, up 21% over Q2 2025; GAAP net income of $45.1 million included a $42.4 million non-cash income tax benefit; adjusted EBITDA was $7.4 million, or 26% of revenue.
Revenue grew 21% year over year and 4% sequentially, while GAAP and adjusted operating results improved materially and adjusted EBITDA margin increased to 26% of revenue. The reported GAAP net-income result was substantially affected by a $42.4 million non-cash income tax benefit, and gross-margin comparisons declined year over year.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Total revenue, three months ended June 30, 2026GAAP | $28.5 million | 4% | 21% |
| Total revenue, six months ended June 30, 2026GAAP | $56.0 million | – | 23% |
| Cost of revenue, three months ended June 30, 2026GAAP | $10,179 | – | – |
| Cost of revenue, six months ended June 30, 2026GAAP | $20,182 | – | – |
| Gross profit, three months ended June 30, 2026GAAP | $18,287 | – | – |
| Gross profit, six months ended June 30, 2026GAAP | $35,784 | – | – |
| Gross margin, three months ended June 30, 2026GAAP | 64% | – | – |
| Adjusted gross margin, three months ended June 30, 2026non-GAAP | 65% | – | – |
| Gross margin, six months ended June 30, 2026GAAP | 64% | – | – |
| Adjusted gross margin, six months ended June 30, 2026non-GAAP | 65% | – | – |
| General and administrative expense, three months ended June 30, 2026GAAP | $10,694 | – | – |
| General and administrative expense, six months ended June 30, 2026GAAP | $22,901 | – | – |
| Sales and marketing expense, three months ended June 30, 2026GAAP | $2,782 | – | – |
| Sales and marketing expense, six months ended June 30, 2026GAAP | $5,308 | – | – |
| Research and development expense, three months ended June 30, 2026GAAP | $2,958 | – | – |
| Research and development expense, six months ended June 30, 2026GAAP | $5,608 | – | – |
| IPR&D expense, three months ended June 30, 2026GAAP | — | – | – |
| IPR&D expense, six months ended June 30, 2026GAAP | — | – | – |
| Intangible asset amortization, three months ended June 30, 2026GAAP | $157 | – | – |
| Intangible asset amortization, six months ended June 30, 2026GAAP | $242 | – | – |
| Total operating expenses, three months ended June 30, 2026GAAP | $16,591 | – | – |
| Total operating expenses, six months ended June 30, 2026GAAP | $34,059 | – | – |
| Operating income, three months ended June 30, 2026GAAP | $1.7 million | – | – |
| Adjusted operating income, three months ended June 30, 2026non-GAAP | $3.1 million | – | – |
| Operating income, six months ended June 30, 2026GAAP | $1.7 million | – | – |
| Adjusted operating income, six months ended June 30, 2026non-GAAP | $4.1 million | – | – |
| Interest income, net, three months ended June 30, 2026GAAP | $994 | – | – |
| Interest income, net, six months ended June 30, 2026GAAP | $2,035 | – | – |
| Other income, three months ended June 30, 2026GAAP | $63 | – | – |
| Other income, six months ended June 30, 2026GAAP | $242 | – | – |
| Total other income, net, three months ended June 30, 2026GAAP | $1,057 | – | – |
| Total other income, net, six months ended June 30, 2026GAAP | $2,277 | – | – |
| Net income, three months ended June 30, 2026GAAP | $45.1 million | – | – |
| Adjusted net income, three months ended June 30, 2026non-GAAP | $4.2 million | – | – |
| Net income, six months ended June 30, 2026GAAP | $46.3 million | – | – |
| Adjusted net income, six months ended June 30, 2026non-GAAP | $6.3 million | – | – |
| Net income per share, three months ended June 30, 2026GAAP | $0.92 | – | – |
| Net income per share, six months ended June 30, 2026GAAP | $0.95 | – | – |
| Adjusted EBITDA, three months ended June 30, 2026non-GAAP | $7.4 million, or 26% of revenue | – | – |
| Adjusted EBITDA, six months ended June 30, 2026non-GAAP | $13.5 million, or 24% of revenue | – | – |
What drove it
- Total revenue increased $5.0 million, or 21%, from the second quarter of 2025 and increased $1.0 million, or 4%, from the first quarter of 2026.
- Management said performance was led by its market-leading biopreservation media franchise.
- Biopreservation media was utilized in approximately 250 ongoing commercially sponsored clinical trials in the U.S., representing a more than 70% market share, including over 30 Phase III trials, or nearly 80% of these late-stage trials.
- Biopreservation media was embedded in 18 unique commercial CGTs as of June 30, 2026. CellSeal cryogenic vials and hPL products were embedded in four approved therapies.
- The release of the valuation allowance during the second quarter of 2026 generated a $42.4 million non-cash income tax benefit.
Concerns
- GAAP gross margin was 64% versus 65% for the second quarter of 2025, while adjusted gross margin was 65% versus 66%.
- The $42.4 million non-cash income tax benefit had an $0.87 impact on second-quarter GAAP net income per share.
- Research and development expense was $2,958 for the three months ended June 30, 2026, versus $1,965 for the prior-year period.
- The pending acquisition means BioLife will cease to be a publicly traded company if the merger is completed.
What to watch
- Closing of Repligen's acquisition of BioLife, which is expected to close in the fourth quarter of 2026, subject to stockholder approval, regulatory approvals and other customary closing conditions.
- Management expects approvals for 8 additional products, geographic expansions, earlier lines of treatment, or new indications over the next 12 months.
- Progress of CellSeal vials and hPL products, which are used in over 35 clinical trials.
Balance sheet and cash flow
- Cash, cash equivalents, and marketable securities as of June 30, 2026 were $113.1 million.
Analysis
BioLife reported second-quarter total revenue of $28.5 million, up $5.0 million, or 21%, from the second quarter of 2025 and up $1.0 million, or 4%, from the first quarter of 2026. For the six months ended June 30, 2026, revenue was $56.0 million, up $10.5 million, or 23%, from the comparable 2025 period. Management attributed quarterly execution to its biopreservation media franchise.
Profitability improved substantially from the prior-year quarter. GAAP operating income was $1.7 million compared with an operating loss of $16.1 million, while adjusted operating income was $3.1 million compared with an adjusted operating loss of $0.3 million. Adjusted EBITDA rose to $7.4 million, or 26% of revenue, from $5.6 million, or 24% of revenue. The operating comparison also reflects the absence of $15,521 of IPR&D expense recorded in the prior-year quarter.
Margins warrant attention despite the improved operating result. GAAP gross margin was 64%, compared with 65% in the second quarter of 2025, and adjusted gross margin was 65%, compared with 66%. Research and development expense increased to $2,958 from $1,965 in the prior-year quarter. GAAP net income of $45.1 million and GAAP net income per share of $0.92 were materially affected by the $42.4 million non-cash income tax benefit from releasing the valuation allowance, which had an $0.87 impact on net income per share. Adjusted net income was $4.2 million.
The balance sheet included $113.1 million of cash, cash equivalents, and marketable securities as of June 30, 2026. The company did not provide financial operating guidance and will not host a conference call due to the pending Repligen acquisition. Repligen agreed on July 21, 2026 to acquire BioLife for an approximate total enterprise value of $1.5 billion, consisting of $11.25 cash and 0.1442 shares of Repligen common stock per BioLife common share. The transaction is expected to close in the fourth quarter of 2026, subject to stated closing conditions.
Management, verbatim
We delivered another strong quarter, with solid execution across the business led by our market-leading biopreservation media franchise.
Roderick de Greef, Chairman and Chief Executive Officer of BioLife
Not in the filing
stated, not guessed- Segment revenue and segment-level growth were not reported.
- Forward financial guidance for revenue, gross margin, operating expenses, tax rate, or other operating metrics was not provided.
- Prior outlook was not provided.
- Adjusted earnings per share was not provided in the supplied filing text.
- Operating cash flow and free cash flow were not provided.
- Debt balances were not provided.
- Share repurchases and dividends were not provided.
- A full balance-sheet presentation was not provided in the supplied filing text.
- The supplied statement-of-operations excerpt is truncated after the income-before-income-tax line; subsequent statement line items are not available.
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
BioLife Solutions filed an SEC 8-K (Item 2.02) with Q2 2026 financial results and details of a definitive acquisition agreement by Repligen.
Ticker impact
BioLife reports Q2 2026 results and discloses Repligen’s definitive agreement to acquire BLFS for about $1.5B, expected to close in Q4 2026.
Near-term trading likely follows deal-spread dynamics and deal-close probability, while the reported profitability improvement may support downside protection.
The 8-K includes a definitive acquisition agreement with stated consideration and an expected Q4 2026 close, which is typically the dominant driver versus quarterly operating metrics.
Market effects
CGT supply-chain and biopreservation tooling names may see read-across interest as consolidation signals strategic value of preservation media franchises.
Limited direct regional impact; primary effect is on US-listed CGT tooling sentiment and M&A expectations.
Moderate global relevance for cell and gene therapy infrastructure providers, but the disclosed catalyst is company-specific.
Counterpoint
The GAAP net income surge is heavily driven by a non-cash income tax benefit from valuation allowance release, which may not reflect sustainable operating momentum.
Key entities
- public_companyBioLife Solutions, Inc.
Nasdaq-listed cell processing tools and services provider reporting Q2 2026 results and announcing it will be acquired by Repligen.
- public_companyRepligen
Acquirer in the definitive agreement to purchase BioLife for about $1.5B, expected to close in Q4 2026.
